Hassan Raffit, Kreitman Robert J, Pastan Ira, Willingham Mark C
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4264, USA.
Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7. doi: 10.1097/01.pai.00000141545.36485.d6.
Mesothelin is a cell surface glycoprotein that is present on normal mesothelial cells and overexpressed in several cancers. On immunohistochemical examination of a limited number of ovarian tumors, increased mesothelin expression has been previously noted. The authors evaluated mesothelin expression in 48 patients with ovarian cancer who were screened for participation in phase 1 studies of a recombinant immunotoxin targeting mesothelin. Eligibility criteria for participation in the studies included mesothelin expression by more than 30% of accessible tumor cells. Sections of formalin-fixed paraffin-embedded tumor specimens were evaluated for mesothelin expression by immunohistochemistry using the anti-mesothelin monoclonal antibody K1. Between September 2000 and January 2003, 48 ovarian tumors were analyzed for mesothelin positivity. Mesothelin positivity was noted in 34 of the 48 cases evaluated (71%). These results show that mesothelin is expressed in most epithelial ovarian cancers and that mesothelin expression in ovarian cancers can be evaluated in archival material. Patients whose tumors express mesothelin could be eligible for participation in clinical trials of novel agents targeting mesothelin.
间皮素是一种细胞表面糖蛋白,存在于正常间皮细胞上,并在多种癌症中过度表达。在对少数卵巢肿瘤进行免疫组织化学检查时,此前已注意到间皮素表达增加。作者评估了48例卵巢癌患者的间皮素表达情况,这些患者被筛选以参与针对间皮素的重组免疫毒素的1期研究。参与研究的入选标准包括超过30%的可及肿瘤细胞表达间皮素。使用抗间皮素单克隆抗体K1通过免疫组织化学对福尔马林固定石蜡包埋肿瘤标本的切片进行间皮素表达评估。在2000年9月至2003年1月期间,对48个卵巢肿瘤进行了间皮素阳性分析。在评估的48例病例中有34例(71%)检测到间皮素阳性。这些结果表明,间皮素在大多数上皮性卵巢癌中表达,并且卵巢癌中间皮素的表达可以在存档材料中进行评估。肿瘤表达间皮素的患者可能有资格参与针对间皮素的新型药物的临床试验。